March 2009
Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p2
Trade Publication
This article reports on an initial clinical trial conducted by CombiMatrix Corp. for its novel anticancer drug LC-1 in 2009. CombiMatrix has announced that Leuchemix provided additional information regarding the initial trial. Results so far suggest that the drug could be particularly useful in patients who have previously responded badly to conventional chemotherapy.


Related Articles

  • LITERATURE MONITOR. Theuvenin, Frederique H. // Pulmonary Reviews;Nov2010, Vol. 15 Issue 11, p19 

    The article presents information on recently published clinical reports related to pulmonary diseases. The efficacy and safety of erlotinib in treating patients with advanced non-small cell lung cancer (NSCLC) was confirmed in a phase IV trial whose findings were published in the October 2010...

  • Oral fingolimod was more effective than intramuscular interferon for relapsing-remitting multiple sclerosis. Hughes, James // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p5 

    The article presents a study that discusses the effective use of oral fingolimod and intramuscular interferon β in patients with relapsing-remitting multiple sclerosis (MS). Reportedly, doses of oral fingolimod and interferon β were given to thousands of patients during the clinical trail...

  • Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines. Zhou, Jun; Oliveira, Paula; Xueli Li; Zhengming Chen; Bepler, Gerold // Journal of Nucleic Acids;2010, p1 

    RRM1 is a determinant of gemcitabine efficacy in cancer patients. However, the precision of predicting tumor response based on RRM1 levels is not optimal. We used gene-specific overexpression and RNA interference to assess RRM1's impact on different classes of cytotoxic agents, on drug-drug...

  • Advances in using PARP inhibitors to treat cancer.  // BMC Medicine;2012, Vol. 10 Issue 1, p25 

    The article presents a study on advances in using poly (ADP-ribose) polymerase (PARP) inhibitors to treat cancer. Several PARP inhibitors are in clinical development; as a whole, these agents have generated considerable interest because of their potential clinical activity for patients whose...

  • IU cancer center studies ImClone drug. Maurer, Katie // Indianapolis Business Journal;7/14/2003, Vol. 24 Issue 18, p43 

    Reports on the clinical trials of the anticancer drug Erbitux.

  • Sch-66336 (Sarasar�) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations. A.G. Taveras; P. Kirschmeier; C.M. Baum // Current Topics in Medicinal Chemistry;Jun2003, Vol. 3 Issue 10, p1103 

    Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials. Sch-66336 (sarasar�), a benzocycloheptapyridyl Farnesyl Transferase Inhibitor (FTI), has been found to be effective in cellular proliferation assays and in in...

  • Trial Watch.  // Nature Reviews Cancer;Jul2002, Vol. 2 Issue 7, p482 

    Presents findings of clinical trials of candidate antineoplastic drugs recent as of July 2002. Pharmacokinetics and pharmacodynamics of the modified adenoviral vector INGN-241 in patients with advanced carcinoma; Phase I clinical trial of a novel molecule designed to inhibit signaling by the...

  • Clinical trial design changing as molecular targets gain popularity. Hollon, Tom; Hollon, T // JNCI: Journal of the National Cancer Institute;12/5/2001, Vol. 93 Issue 23, p1770 

    Investigates the clinical trial designs for drugs with cytotoxic properties. Identification of cell growth; Observation of solid tumor; Formation of the monoclonal antibody.

  • 1133. A Phase I Study of Antitumor Vaccination Using Genetically Modified Tumor Cells Expressing α(1,3)Galactosyltransferase in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer (NSCLC): Preliminary Results Morris, John C.; Janik, John E.; Vahanian, Nicholas; Moses, Leslie; O'Hagan, Diana; Tennant, Lucinda; Pittaluga, Stefania; Gao, Wendy; Albert, Paul; Seregina, Tatiana; Link, Charles J. // Molecular Therapy;Jun2005, Vol. 11, p437 

    An abstract of the article "A Phase I Study of Antitumor Vaccination Using Genetically Modified Tumor Cells Expressing α(1,3)Galactosyltransferase in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer (NSCLC): Preliminary Results," by John C. Morris and colleagues is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics